Flu vaccine selection
Executive Summary
Vaccines & Related Biological Products Advisory Committee postpones until mid-March selection of influenza A H3N2 vaccine strain for 2003-2004 flu season pending further analysis of new virus strains. Current vaccine strain, A/Panama/2007/99, has been ineffective at inhibiting recent strains marked by altered amino acid sequence, FDA and CDC reps said during Feb. 20 meeting. FDA committee is expected to hold teleconference March 17 or 18 on strain selection, at which time the panel also could hear data about occurrence of avian influenza virus (A H5N1) in Hong Kong. Committee voted to retain current A H1N1 (New Caledonia/20/99) and B (Hong Kong/330/2001 and 1434/02) strains...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.